IL155273A0 - Pharmaceutical compositions comprising an aplidine compound - Google Patents

Pharmaceutical compositions comprising an aplidine compound

Info

Publication number
IL155273A0
IL155273A0 IL15527301A IL15527301A IL155273A0 IL 155273 A0 IL155273 A0 IL 155273A0 IL 15527301 A IL15527301 A IL 15527301A IL 15527301 A IL15527301 A IL 15527301A IL 155273 A0 IL155273 A0 IL 155273A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
aplidine
aplidine compound
compound
carnitine
Prior art date
Application number
IL15527301A
Other languages
English (en)
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0025044A external-priority patent/GB0025044D0/en
Priority claimed from GB0025209A external-priority patent/GB0025209D0/en
Priority claimed from PCT/GB2000/004349 external-priority patent/WO2001035974A2/en
Priority claimed from GB0107373A external-priority patent/GB0107373D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Priority claimed from PCT/GB2001/004555 external-priority patent/WO2002030441A2/en
Publication of IL155273A0 publication Critical patent/IL155273A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IL15527301A 2000-10-12 2001-10-12 Pharmaceutical compositions comprising an aplidine compound IL155273A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0025044A GB0025044D0 (en) 2000-10-12 2000-10-12 Toxicity protection
GB0025209A GB0025209D0 (en) 2000-10-13 2000-10-13 Treatment of cancers
PCT/GB2000/004349 WO2001035974A2 (en) 1999-11-15 2000-11-15 Aplidine treatment of cancers
GB0107373A GB0107373D0 (en) 2001-03-23 2001-03-23 Aplidine
PCT/GB2001/004555 WO2002030441A2 (en) 2000-10-12 2001-10-12 Treatment of cancers by aplidine in conjunction with a myoprotector

Publications (1)

Publication Number Publication Date
IL155273A0 true IL155273A0 (en) 2003-11-23

Family

ID=27255931

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15527301A IL155273A0 (en) 2000-10-12 2001-10-12 Pharmaceutical compositions comprising an aplidine compound

Country Status (14)

Country Link
US (1) US7507766B2 (xx)
JP (1) JP2010031043A (xx)
KR (1) KR20030038812A (xx)
CN (1) CN1479622A (xx)
AT (1) ATE299028T1 (xx)
BR (1) BR0114604A (xx)
CZ (1) CZ2003993A3 (xx)
ES (1) ES2243555T3 (xx)
HK (1) HK1054191A1 (xx)
IL (1) IL155273A0 (xx)
NO (1) NO20031673L (xx)
NZ (1) NZ525196A (xx)
PL (1) PL361179A1 (xx)
RU (1) RU2003113210A (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02004862A (es) * 1999-11-15 2003-01-28 Pharma Mar Sa Tratamiento de aplidina para canceres.
RU2341283C2 (ru) * 2003-03-12 2008-12-20 Фарма Мар, С.А. Усовершенствованное лечение опухолей
EP1942944A2 (en) * 2005-10-31 2008-07-16 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
PL2029155T3 (pl) * 2006-02-28 2016-09-30 Ulepszony sposób leczenia szpiczaka mnogiego
CA2703024A1 (en) * 2007-10-19 2009-04-23 Giuseppe Longo Sorbello Improved antitumoral treatments
KR20100131474A (ko) * 2008-03-07 2010-12-15 파르마 마르 에스.에이. 개선된 항암치료
US8809562B2 (en) 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
ATE196844T1 (de) * 1996-05-22 2000-10-15 Protarga Inc Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
DK0918693T3 (da) 1996-07-03 2002-03-04 Paxton C G Ltd Beholdere
AU726146B2 (en) 1996-10-24 2000-11-02 Board Of Trustees Of The University Of Illinois, The Total synthesis of the amino hip analogue of didemnin A
ATE321773T1 (de) 1996-10-24 2006-04-15 Univ Illinois Semisynthetisches verfahren zur herstellung von didemninanalogen
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
US6030943A (en) * 1997-05-07 2000-02-29 Crumb; William J. Dehydrodidemnin B as an L-type calcium channel enhancer
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
ES2235499T3 (es) * 1998-07-30 2005-07-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Uso de derivados de propionil l-carnitina y de acetil l-carnitina en la preparacion de medicamentos con actividad anticancerigena.
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
JP2003500360A (ja) 1999-05-25 2003-01-07 ポイント セラピューティクス， インコーポレイテッド ボロプロリン化合物類を含む抗癌剤
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
MXPA02004862A (es) 1999-11-15 2003-01-28 Pharma Mar Sa Tratamiento de aplidina para canceres.
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
CA2405779A1 (en) 2000-04-07 2001-10-18 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
US7175849B2 (en) * 2000-10-05 2007-02-13 Immunex Corporation Nectin polypeptides
EP1330254B1 (en) 2000-10-12 2005-07-06 Pharma Mar, S.A. Treatment of cancers by aplidine in conjunction with carnitine or acetylcarnitine
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
WO2003033013A1 (en) 2001-10-19 2003-04-24 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
RU2341283C2 (ru) 2003-03-12 2008-12-20 Фарма Мар, С.А. Усовершенствованное лечение опухолей

Also Published As

Publication number Publication date
HK1054191A1 (zh) 2003-11-21
CZ2003993A3 (cs) 2004-02-18
RU2003113210A (ru) 2004-11-27
JP2010031043A (ja) 2010-02-12
US7507766B2 (en) 2009-03-24
CN1479622A (zh) 2004-03-03
ATE299028T1 (de) 2005-07-15
NZ525196A (en) 2004-09-24
BR0114604A (pt) 2003-10-14
ES2243555T3 (es) 2005-12-01
US20040010043A1 (en) 2004-01-15
PL361179A1 (en) 2004-09-20
KR20030038812A (ko) 2003-05-16
NO20031673L (no) 2003-06-12
NO20031673D0 (no) 2003-04-11

Similar Documents

Publication Publication Date Title
HUP0200503A2 (en) N-cyanomethyl amides as protease inhibitors and pharmaceutical compositions containing them
MXPA04008772A (es) Composiciones de clorhidrato de naltrexona.
MY129406A (en) Taste masked liquid pharmaceutical compositions
MY129356A (en) Electrospun pharmaceutical compositions
AU7326801A (en) Compositions containing therapeutically active components having enhanced solubility
HUP0103464A3 (en) Prodrugs of proton pump inhibitors and pharmaceutical compositions containing them
DK1157037T3 (da) GCSF-konjugater
AP1450A (en) Solid oral dosage form comprising a combination of metformin and glibenclamide.
MY134190A (en) Compositions and methods for stimulating gastrointestinal motility.
HK1070305A1 (en) Pharmaceutical composition comprising gabapentin or an analogue thereof and an sg(a)-aminoamide and its analgesic use
YU75701A (sh) Farmaceutski preparat
ID27503A (id) Tts yang mengandung antioksidan
HUP0302922A3 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation and pharmaceutical compositions containing them
IL119989A0 (en) Pharmaceutical compositions for oral treatment of multiple sclerosis
NZ503308A (en) Alpha-ketoamide multicatalytic protease inhibitors
HUP0301240A3 (en) Pyridazine compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors and pharmaceutical compositions containing them
EP1492544A4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING PROPOFOL-BASED WATER-SOLUBLE PRODRUGS AND METHODS OF ADMINISTRATION THEREOF
IT1302682B1 (it) Composizioni farmaceutiche orali contenenti buprenorfina
HUP0103382A3 (en) Naaladase inhibitors useful as pharmaceutical compounds and compositions
HUP0400494A3 (en) Polyamine analogues as cytotoxic agents and pharmaceutical compositions containing them
IL155273A0 (en) Pharmaceutical compositions comprising an aplidine compound
HUP0303636A3 (en) Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient
WO2002030441A3 (en) Treatment of cancers by aplidine in conjunction with a myoprotector
WO2002026324A3 (en) Tocol-based compositions containing amiodarone
EP1117681A4 (en) NEW PEPTIDES